TCI Wealth Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

TCI Wealth Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	2252
2020 Q4	$0	Hold	1	–	–	﹤0.01%	1690
2020 Q3	$0	Hold	1	–	–	﹤0.01%	1685
2020 Q2	$0	Hold	1	–	–	﹤0.01%	1705
2020 Q1	$0	Hold	1	–	–	﹤0.01%	1805
2019 Q4	$0	Hold	1	–	–	﹤0.01%	1706
2019 Q3	$0	Hold	1	–	–	﹤0.01%	1655
2019 Q2	$0	Hold	1	–	–	﹤0.01%	1572
2019 Q1	$0	Hold	1	–	–	﹤0.01%	1573
2018 Q4	$0	Hold	1	–	–	﹤0.01%	1696
2018 Q3	$0	Hold	1	–	–	﹤0.01%	1612
2018 Q2	$0	Hold	1	–	–	﹤0.01%	1622
2018 Q1	$0	Hold	1	–	–	﹤0.01%	1448
2017 Q4	$0	Hold	1	–	–	﹤0.01%	1430
2017 Q3	$0	Hold	1	–	–	﹤0.01%	1399
2017 Q2	$0	Hold	1	–	–	﹤0.01%	1388
2017 Q1	$0	Hold	1	–	–	﹤0.01%	1399
2016 Q4	$0	Hold	1	–	–	﹤0.01%	1465
2016 Q3	$0	Hold	1	–	–	﹤0.01%	1416
2016 Q2	$0	Hold	1	–	–	﹤0.01%	1392
2016 Q1	$0	Hold	1	–	–	﹤0.01%	1425
2015 Q4	$0	Hold	1	–	–	﹤0.01%	1097
2015 Q3	$0	Hold	1	–	–	﹤0.01%	1027
2015 Q2	$0	Hold	1	–	–	﹤0.01%	1015
2015 Q1	$0	Hold	1	–	–	﹤0.01%	972
2014 Q4	$0	Hold	1	–	–	﹤0.01%	936
2014 Q3	$1K	Buy	+1	New	+$1.45K	﹤0.01%	841

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCI Wealth Advisors's VIRX Position: Q1 2021 in Review

TCI Wealth Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2021, closing a stake of 1 share.

TCI Wealth Advisors first reported a position in VIRX in Q3 2014 and held it in 26 quarters. The position peaked at $1K in Q3 2014. 50 funds tracked by Wall St. Rank hold VIRX as of Q1 2021.

TCI Wealth Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
TCI Wealth Advisors sold 1 Viracta Therapeutics, Inc. Common Stock share in Q1 2021.
TCI Wealth Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2014 and held it in 26 quarters.
TCI Wealth Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2014.
50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2021.

Based on TCI Wealth Advisors's 13F filing for Q1 2021, filed 29 Apr 2021.